6-(苄氧基)-1H-吲唑 | 874668-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-(苄氧基)-1H-吲唑
• 英文名称: 6-(benzyloxy)1-H-indazole
• 英文别名: 6-(benzyloxy)indazole；6-phenylmethoxy-1H-indazole；JK43；6-(Benzyloxy)-1H-indazole
• CAS: 874668-62-9
• 化学式: C₁₄H₁₂N₂O
• mdl: MFCD05664005
• 分子量: 224.262
• InChiKey: PMKBUGNQHOFKQS-UHFFFAOYSA-N

物化性质

• 沸点：
  422.4±20.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Benzyloxy-1h-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Benzyloxy-1h-indazole
CAS number: 874668-62-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H12N2O
Molecular weight: 224.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(苄氧基)-1H-吲唑 在 palladium on activated charcoal 甲酸铵 、 sodium ethanolate 、 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 37.25h， 生成 [(S)-2-(6-羟基吲唑-1-基)-1-甲基乙基]氨基甲酸苄酯
  参考文献：
  名称：

  1-（（（S）-2-氨丙基）-1H-吲唑-6-ol）：一种有效的外周作用5-HT2受体激动剂，具有降眼压活性。

  摘要：

  5-羟色胺5-HT（2）受体激动剂已被确定为治疗高眼压和青光眼的一种潜在的新型药物。最初报道的色胺类似物要么显示出较差的溶液稳定性，有效的中枢神经系统活性，要么显示出这两种不良特性，并且对于临床评估而言是不可接受的。合成了一系列1-（2-氨基丙基）-1H-吲唑类似物，并评估了其作为临床候选药物的适用性。1-（（S）-2-氨基丙基）-1H-吲唑-6-ol（9）被确定为具有外围作用的有效5-HT（2）受体激动剂（EC（50）= 42.7 nM，E（max = 89％）具有相对于其他血清素能受体亚型和其他受体家族的5-HT（2）受体高选择性，并且溶液稳定性比α-甲基-5-羟基色胺更为显着。此外，有9剂可有效降低自觉性高眼压猴子的眼内压（-13 mmHg，33％）；这种减少似乎是通过局部而不是中央介导的作用。化合物9似乎是出色的5-HT（2）受体激动剂，可用于进行进一步的研究，以针对此类眼用降压药进行概念验证的临床研究。

  DOI：

  10.1021/jm050663x
• 作为产物：
  描述：

  4-苯甲氧基-2-羟基苯甲醛 在 hydrazine hydro-chloride 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 6-(苄氧基)-1H-吲唑
  参考文献：
  名称：

  Synthesis, Antifungal Activity and QSAR of Novel Pyrazole Amides as Succinate Dehydrogenase Inhibitors

  摘要：

  We design and synthesize a series of novel pyrazole amides based on the commercialized fungicides and our previous work. The antifungal activity was tested in vitro by mycelial growth inhibition assay. The results show that all the compounds are of antifungal activities against the tested fungi at different levels. Among them, N-(2-(7-bromo-5-chloro-1H-indazol-1-yl)phenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (Vk) exhibited higher antifungal activity than boscalid against two fungi. Molecular docking study revealed that the carbonyl oxygen atom of Vk forms two hydrogen bonds toward the hydroxyl hydrogens of TYR58 and TRP173.

  DOI：

  10.3987/com-17-13826

文献信息

• INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20160152599A1

  公开（公告）日：2016-06-02

  Compounds of formula (I): wherein R a , R b , R c , R d , R 3 , R 4 , R 5 , A 1 , A 2 , T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式（I）的化合物：其中Ra、Rb、Rc、Rd、R3、R4、R5、A1、A2、T和W的定义如描述中所述。含有这些化合物的药品对治疗涉及凋亡缺陷的病理病变，如癌症、自身免疫疾病和免疫系统疾病等，具有益处。
• [EN] HSD17B13 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE HSD17B13 ET LEURS UTILISATIONS
  申请人：METACRINE INC

  公开号：WO2022072491A1

  公开（公告）日：2022-04-07

  Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.

  本文描述了一些HSD17B13抑制剂化合物，制备这些化合物的方法，包括这些化合物的药物组合物和药物，以及使用这些化合物治疗与HSD17B13活性相关的病症、疾病或障碍的方法。
• [EN] METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE<br/>[FR] PROCEDES DE FABRICATION DE 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE
  申请人：ALCON INC

  公开号：WO2002098861A1

  公开（公告）日：2002-12-12

  Methods of making 1-(2-aminopropyl)-6-hydroxyindazole are described. The method involves, in part, reacting 4-benzyloxy-2-(2-hydroxypropyl)aminobenzaldehyde with an organic or inorganic nitrite to form 4-benzyloxy-2-(2-hydroxypropyl)nitosaminobenzaldehyde, wich in turn is reacted with a reducing agent with concomitant cyclization to form 6-benzyloxy-1-(2-hydroxypropyl)indazole. The 6-benzyloxy-1-(2-hydroxypropyl)indazole can then be transformed into 1-(2-azidopropyl)-6-benzyloxyindazole which in turn can be converted to the final product.

  描述了制备1-(2-氨丙基)-6-羟基吲唑的方法。该方法包括部分地将4-苄氧基-2-(2-羟基丙基)氨基苯甲醛与有机或无机亚硝酸盐反应，形成4-苄氧基-2-(2-羟基丙基)亚硝胺基苯甲醛，然后与还原剂反应，同时环化形成6-苄氧基-1-(2-羟基丙基)吲唑。然后，6-苄氧基-1-(2-羟基丙基)吲唑可以转化为1-(2-叠氮丙基)-6-苄氧基吲唑，随后可以转化为最终产物。
• Cinnoline derivatives as phosphodiesterase 10 inhibitors
  申请人：Hitchcock A. Stephen

  公开号：US20070265270A1

  公开（公告）日：2007-11-15

  The present invention is directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and process for preparing such compounds. The invention is also directed to methods of treating diseases treatable by modulation of PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及某些香豆素化合物，它们是PDE10抑制剂，包含这些化合物的制药组合物以及制备这些化合物的方法。本发明还涉及治疗可通过调节PDE10酶治疗的疾病的方法，如肥胖症、非胰岛素依赖性糖尿病、精神分裂症、双相障碍、强迫症等。
• Indazole derivatives as novel inhibitors of monoamine oxidase and D-amino acid oxidase
  作者：Chezélle Stear、Anél Petzer、Chantalle Crous、Jacobus P. Petzer

  DOI：10.1007/s00044-023-03176-x

  日期：2024.1

  Further investigation of a selected indazole derivative showed a competitive mode of MAO inhibition. To further explore the pharmacological properties of the indazole derivatives, they were also evaluated as potential inhibitors of porcine D-amino acid oxidase (DAAO). None of the synthetic compounds were noteworthy DAAO inhibitors, however, 1H-indazol-5-ol, a synthetic precursor, was found to be a

  单胺氧化酶 (MAO) 酶在外周和中枢组织中代谢神经递质胺，这些酶的抑制剂可用于治疗神经精神和神经退行性疾病。基于神经元一氧化氮合酶 (nNOS) 抑制剂 7-硝基吲唑抑制 MAO-B 亚型的报道，本研究研究了一系列合成的 15 种 C5 和 C6 取代吲唑衍生物的 MAO 抑制效力。虽然只有一种衍生物 (5c) 是人 MAO-A 的亚微摩尔抑制剂 (IC 50 = 0.745 µM)，但所有化合物均以亚微摩尔 IC 50值 抑制人 MAO-B 。 C5 取代吲唑可产生特别有效的 MAO-B 抑制作用，IC 50值范围为 0.0025–0.024 µM。对选定的吲唑衍生物的进一步研究显示了 MAO 抑制的竞争模式。为了进一步探索吲唑衍生物的药理学特性，还对它们作为猪 D-氨基酸氧化酶 (DAAO) 的潜在抑制剂进行了评估。合成化合物都不是值得注意的 DAAO 抑制剂，然而，合成前体 1 H